Description: Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Home Page: www.tarsusrx.com
TARS Technical Analysis
15440 Laguna Canyon Road
Irvine,
CA
92618
United States
Phone:
949 409 9820
Officers
| Name | Title |
|---|---|
| Dr. Bobak R. Azamian M.D. | Co-Founder, Pres, CEO & Chairman |
| Dr. Bryan Wahl J.D., M.D. | Gen. Counsel & Corp. Sec. |
| Ms. Dianne C. Whitfield M.S.W. | Chief HR Officer |
| Dr. Elizabeth Yeu Lin M.D. | Chief Medical Advisor & Director |
| Dr. D. Michael Ackermann Ph.D. | Consultant |
| Mr. Leonard M. Greenstein J.D. | Chief Financial Officer |
| Dr. Seshadri Neervannan Ph.D. | Chief Operating Officer |
| Mr. David Nakasone | Head of Investor Relations |
| Ms. Adrienne Kemp | Sr. Director of Corp. Communications |
| Mr. Matthew Rossen M.B.A. | VP of Marketing |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0377 |
| Price-to-Sales TTM: | 24.7503 |
| IPO Date: | 2020-10-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 46 |